BNB Plus Corp., formerly Applied DNA Sciences, Inc., reports corporate developments tied to its transition from the APDN ticker to BNBX, its BNB-focused digital asset treasury strategy, and its remaining nucleic acid production business. Company news has covered ticker and name changes, Nasdaq listing compliance, restructuring actions, financing activity, and governance changes.
The company's biotechnology updates have centered on LineaRx, LineaDNA, LineaIVT, and LineaRNAP, including synthetic DNA and mRNA manufacturing applications for biopharmaceutical, diagnostic, gene therapy, personalized medicine, adoptive cell therapy, mRNA therapeutic, and DNA vaccine markets.
Applied DNA Sciences (NASDAQ: APDN) has signed a Master Services Agreement with Stony Brook University Hospital to supply its EUA authorized LineaTM COVID-19 Assay Kit for diagnostic testing. This one-year agreement includes the implementation of a high-throughput automation workflow for COVID-19 testing, enhancing operational flexibility and testing capacity at SBUH. The Assay Kit can utilize various sample types, including anterior nasal and nasopharyngeal swabs. Initial purchase order details remain undisclosed.